Cooper : Guidance

Q4 2023 Guidance

FY23 Guidance*

Total

$912 - $929

$3,578 - $3,595

(7% - 9% organic growth)

(9% - 10% organic growth)

Sales

CooperVision

$613 - $624

$2,414 - $2,425

(8% - 10% organic growth)

(10% - 11% organic growth)

CooperSurgical

$299 - $305

$1,164 - $1,170

(5% - 7% organic growth)

(7% - 8% organic growth)

EPS

Non-GAAP

$3.39 - $3.57

$12.72 - $12.90

Note: Sales $ in millions; Organic growth excludes the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures, or discontinuations that occurred in the comparable period.

Non-GAAP and organic - a reconciliation of these measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's

1

Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's

website:www.coopercos.com.

*Guidance updated 8/30/23.